sanofi-aventis, Chattem Inc., KaloBios deal

sanofi-aventis' Sanofi Pasteur S.A. vaccines division received exclusive, worldwide rights to develop and commercialize KaloBios' KB001 to treat and prevent Pseudomonas aeruginosa infections, except in cystic fibrosis and bronchiectasis indications. The humanized antibody fragment against PcrV (V-antigen) on P. aeruginosa has completed Phase I/II trials in mechanically ventilated patients and CF patients with P. aeruginosa infections. KaloBios will receive $35 million up front and is eligible for $255 million in milestones, plus royalties. Sanofi Pasteur has an option to acquire commercial rights from KB001 for CF and bronchiectasis outside the U.S., as well as co-promotion rights in the U.S. ...